×
Choose Speciality

EXPLORE!

LOGIN

By signing up or signing in to eMediNexus, you consent to eMediNexus collecting and using your personal data in accordance with our Privacy Policy. We are committed to safeguarding your information and ensuring the highest standards of data protection. Your trust and privacy are of utmost importance to us.

FDA expands approval of Sutent to reduce the risk of recurrence of kidney cancer

  869 Views

eMediNexus    18 November 2017

The US Food and Drug Administration FDA has approved Sutent sunitinib malate for the adjuvant treatment of adult patients who are at a high risk of kidney cancer renal cell carcinoma returning after a kidney has been removed nephrectomy . Adjuvant treatment is a form of therapy that is taken after an initial surgical removal to lower the risk of the cancer coming back.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.